Index RUT P/E - EPS (ttm) -2.15 Insider Own 39.99% Shs Outstand 44.57M Perf Week -1.04%
Market Cap 636.75M Forward P/E - EPS next Y -2.07 Insider Trans 0.00% Shs Float 26.76M Perf Month 22.16%
Enterprise Value 334.76M PEG - EPS next Q 0.04 Inst Own 63.18% Short Float 11.52% Perf Quarter 37.18%
Income -87.50M P/S 872.25 EPS this Y 95.16% Inst Trans -3.16% Short Ratio 10.11 Perf Half Y 123.47%
Sales 0.73M P/B 1.69 EPS next Y -490.28% ROA -29.57% Short Interest 3.08M Perf YTD -37.64%
Book/sh 8.47 P/C 1.95 EPS next 5Y 25.47% ROE -32.78% 52W High 28.99 -50.74% Perf Year -
Cash/sh 7.32 P/FCF - EPS past 3/5Y -56.62% -ROIC -21.87% 52W Low 4.17 242.45% Perf 3Y -
Dividend Est. - EV/EBITDA - Sales past 3/5Y - - Gross Margin -113.36% Volatility 5.50% 5.69% Perf 5Y -
Dividend TTM - EV/Sales 458.57 EPS Y/Y TTM -1025.90% Oper. Margin -14071.07% ATR (14) 0.72 Perf 10Y -
Dividend Ex-Date - Quick Ratio 22.09 Sales Y/Y TTM -13.37% Profit Margin -12053.03% RSI (14) 63.17 Recom 1.40
Dividend Gr. 3/5Y - - Current Ratio 22.09 EPS Q/Q -51.88% SMA20 10.29% Beta - Target Price 24.25
Payout - Debt/Eq 0.07 Sales Q/Q -67.84% SMA50 14.65% Rel Volume 0.53 Prev Close 14.42
Employees 75 LT Debt/Eq 0.06 Earnings Aug 11 AMC SMA200 15.75% Avg Volume 304.75K Price 14.28
IPO Oct 25, 2024 Option/Short Yes / Yes EPS/Sales Surpr. -160.42% -99.70% Trades
Volume 161,795 Change -0.97%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-23-25 Initiated H.C. Wainwright
Buy
$26
Feb-18-25 Downgrade Wells Fargo
Overweight → Equal Weight
$14
Nov-19-24 Initiated Wells Fargo
Overweight
$43
Nov-19-24 Initiated TD Cowen
Buy
Nov-19-24 Initiated JP Morgan
Overweight
$38
Nov-19-24 Initiated Cantor Fitzgerald
Overweight
$50
Aug-27-25 08:00AM
Aug-21-25 08:00AM
Aug-14-25 08:15AM
Aug-11-25 04:01PM
May-29-25 08:00AM
07:45AM
Loading…
May-23-25 07:45AM
May-21-25 09:55AM
May-15-25 04:01PM
10:00AM
08:46AM
07:45AM
01:45AM
(The Wall Street Journal)
May-14-25 04:06PM
(Investor's Business Daily) +50.97%
02:22PM
01:29PM
(Pharmaceutical Technology)
10:28AM
Loading…
10:28AM
09:35AM
09:32AM
09:32AM
07:03AM
Apr-16-25 09:55AM
Mar-31-25 02:34PM
Mar-27-25 08:00AM
Mar-14-25 11:26AM
Mar-05-25 06:59PM
Feb-26-25 08:00AM
Feb-18-25 08:00AM
Feb-14-25 06:45AM
Feb-06-25 07:48AM
Jan-06-25 07:00AM
08:00AM
Loading…
Dec-18-24 08:00AM
Nov-21-24 11:12PM
Nov-20-24 07:00AM
05:10AM
Oct-30-24 04:41PM
Oct-24-24 09:47PM
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Klein Uwe SVP, Biological Sciences Aug 18 '25 Option Exercise 4.10 23,008 94,367 23,008 Aug 19 05:02 PM Finer Jeffrey CEO and President Apr 02 '25 Option Exercise 2.76 50,000 138,000 821,907 Apr 04 04:13 PM Finer Jeffrey CEO and President Apr 03 '25 Option Exercise 2.76 5,000 13,800 826,907 Apr 04 04:13 PM Ezekowitz Alan Director Mar 07 '25 Buy 6.93 13,319 92,270 117,420 Mar 10 04:18 PM Ezekowitz Alan Director Mar 06 '25 Buy 6.00 41,355 248,130 104,101 Mar 06 09:02 PM Ezekowitz Alan Director Mar 05 '25 Buy 5.82 37,835 220,260 62,746 Mar 06 09:02 PM Ezekowitz Alan Director Mar 04 '25 Buy 6.35 7,491 47,544 24,911 Mar 06 09:02 PM Finer Jeffrey CEO and President Feb 25 '25 Buy 5.68 10,000 56,765 764,907 Feb 27 06:53 PM Finer Jeffrey CEO and President Feb 26 '25 Buy 5.70 4,000 22,796 768,907 Feb 27 06:53 PM Finer Jeffrey CEO and President Feb 27 '25 Buy 5.80 3,000 17,400 771,907 Feb 27 06:53 PM Labrucherie Gil M Chief Financial Officer Feb 25 '25 Buy 5.59 6,282 35,116 36,282 Feb 27 06:51 PM Labrucherie Gil M Chief Financial Officer Feb 27 '25 Buy 5.85 3,718 21,750 40,000 Feb 27 06:51 PM Third Rock Ventures VI, L.P. 10% Owner Feb 24 '25 Buy 6.00 18,861 113,147 4,211,659 Feb 26 04:15 PM Third Rock Ventures VI, L.P. 10% Owner Feb 20 '25 Buy 5.92 612,674 3,627,030 3,765,130 Feb 24 04:15 PM Third Rock Ventures VI, L.P. 10% Owner Feb 21 '25 Buy 5.94 427,668 2,540,348 4,192,798 Feb 24 04:15 PM Labrucherie Gil M Chief Financial Officer Feb 20 '25 Buy 5.88 14,500 85,234 25,000 Feb 21 06:06 PM Labrucherie Gil M Chief Financial Officer Feb 19 '25 Buy 5.51 10,500 57,813 10,500 Feb 21 06:06 PM Labrucherie Gil M Chief Financial Officer Feb 21 '25 Buy 5.85 5,000 29,250 30,000 Feb 21 06:06 PM RA CAPITAL MANAGEMENT, L.P. Director Oct 28 '24 Buy 18.00 4,170,000 75,060,000 5,523,915 Oct 30 06:12 PM Third Rock Ventures V, L.P. 10% Owner Oct 28 '24 Buy 18.00 370,500 6,669,000 6,215,591 Oct 28 04:53 PM Third Rock Ventures V, L.P. 10% Owner Oct 28 '24 Buy 18.00 279,500 5,031,000 3,152,456 Oct 28 04:53 PM
